Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from KNSA

Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

5 Biotech Stocks With 26% Upside Potential or More

5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Pharma Stocks to Watch for Value in September

The pharmaceutical industry enjoys robust demand irrespective of economic cycles. Also, given its solid growth prospects, I think pharma stocks Pfizer (PFE), Catalyst Pharmaceuticals (CPRX), and Kiniksa Pharmaceuticals (KNSA) might be worth adding to one’s watchlist for value. Read on.

3 Pharma Stocks to Buy for a Smart Investment

With the rise of chronic diseases and technological advancements, the pharma market looks poised for substantial expansion. So, fundamentally strong pharma stocks Kiniksa Pharmaceuticals (KNSA), Collegium Pharmaceutical (COLL), and Wave Life Sciences (WVE) might be solid buys. Keep reading.

Recap: Kiniksa Pharmaceuticals Q1 Earnings

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Earnings Scheduled For May 3, 2022

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.

inkl

Read news from The Economist, FT, and more,
with one subscription

Kiniksa Pharma, Huadong Medicine Ink Licensing Pact For Arcalyst, Mavrilimumab

Kiniksa Pharma, Huadong Medicine Ink Licensing Pact For Arcalyst, Mavrilimumab

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) and Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd., a subsidiary of Huadong Medicine Co., Ltd., have announced a strategic collaboration to develop and commercialize Kiniksa's Arcalyst and mavrilimumab in the Asia Pacific Region.

Kiniksa Pharmaceuticals: Q4 Earnings Insights

Kiniksa Pharmaceuticals: Q4 Earnings Insights

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported its Q4 earnings results on Tuesday, February 22, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

1

People

Kritika SarmahHer

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

British Petroleum

Paramount Global

Medical Pharmaceuticals

Catalyst Pharmaceuticals Inc

Collegium Pharmaceutical Inc

Wave Life Sciences Ltd

Adaptive Biotechnologies

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play